Yale spinout Arvinas has added cash to its coffers as it prepares oncological treatments for forms of prostate and breast cancer.
Arvinas, a US-based oncological drug developer based on Yale University research, has closed a $55m series C round led by fund management firm Nextech Invest.
Healthcare-focused investment firms OrbiMed and Deerfield Management also provided funding, as did Hillhouse Capital, Sirona Capital, Canaan Partners, 5AM Ventures, RA Capital Management and New Leaf Venture Partners.
Arvinas is developing oncological drugs branded Protac that cause the biological proteins responsible for cancer to degrade by targeting a pathway called the ubiquitin-proteasome system.
The approach…
